Bartosz Damian Walkowski

Mr. Bartosz Damian Walkowski

Medical University of Warsaw, Warsaw, Mazowieckie, Poland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2022 in Cells
Verified
Journal Article
Open access
PDF file
Bartosz Damian WalkowskiBartosz Damian Walkowski
Bartosz Damian Walkowski
MKMarcin Kleibert
Marcin Kleibert
Miłosz MajkaMiłosz Majka
Miłosz Majka
MWMałgorzata Wojciechowska
Małgorzata Wojciechowska
Despite the significant decline in mortality, cardiovascular diseases are still the leading cause of death worldwide. Among them, myocardial infarction (MI) seems to be the most important. A further decline in the death rate may be achieved by the introduction of molecularly targeted drugs. It seems that the components of the PI3K/Akt signaling pathway are good candidates for this. The PI3K/Akt pathway plays a key role in the regulation of the growth and survival of cells, such as cardiomyocytes. In addition, it has been shown that the activation of the PI3K/Akt pathway results in the alleviation of the negative post-infarct changes in the myocardium and is impaired in the state of diabetes. In this article, the role of this pathway was described in each step of ischemia and subsequent left ventricular remodeling. In addition, we point out the most promising substances which need more investigation before introduction into clinical practice. Moreover, we present the impact of diabetes and widely used cardiac and antidiabetic drugs on the PI3K/Akt pathway and discuss the molecular mechanism of its effects on myocardial ischemia and left ventricular remodeling.